Loading the stock brief
Stock brief · the live tape
KYMRKymera Therapeutics, Inc.
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · Nasdaq
$112.40
▼ $3.03 (-2.6%) · 30dclose Friday, October 9, 2026
No member of Congress has disclosed a trade in this ticker.
465 insider filings · 2 tracked funds
The Hillno disclosed congressional trade
The Boardroom
▲ 9▼ 288
9 buys · 288 sells · 465 filingsFeeding Time
▲ 0▼ 1
0 adding · 1 trimming · 2 holdingCAT Scan
50Only one filer stands behind this number, and it is barely off 50.
- Insiders·1 insider bought and 2 sold in the open market, latest 26 Jun
- Funds·1 tracked fund bought or added, latest 17 Feb
- Congress·Nothing counted in the last year
Quiet since 26 Jun
Scored 15 Oct · From public filings. Not a forecast. How it works
The tape
Price with a twin dot per disclosed trade: filled at the trade, hollow at the filing. The dashed gap is what the market did in between, not anyone’s return.
trade (insider)
The boardroom
Scheduled 10b5-1 sales are usually noise, set on autopilot months ago. The unscheduled ones are the ones to read.
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Adams BrianChief Legal OfficerUnscheduled
Adams BrianChief Legal OfficerUnscheduled
Adams BrianChief Legal OfficerUnscheduled
Rooney TerenceChief Medical OfficerUnscheduled
Rooney TerenceChief Medical OfficerUnscheduled
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Goodman NoahChief Business OfficerScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Mainolfi NelloChief Executive Officer, DirectorScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Jacobs Bruce N.Chief Financial OfficerScheduled · 10b5-1
Booth BruceDirectorScheduled · 10b5-1
Booth BruceDirectorScheduled · 10b5-1
Booth BruceDirectorScheduled · 10b5-1
Booth BruceDirectorScheduled · 10b5-1
Booth BruceDirectorScheduled · 10b5-1
The fund book
Tracked 13F holders and how their position moved, quarter over quarter.
Positions as filed for the quarter ending 30 Jun 2026, the latest on file. A 13F is a quarter-end photograph filed up to 45 days later, so this is where these funds stood then, not what they hold now. Common stock only: options and short positions are not in a 13F, and a fund that had already sold out does not appear.
⚠️ Public information, sourced from STOCK Act, Form 4 and 13F filings. Ranges use midpoints. Price paths between a trade and its filing are market moves, not anyone’s return. Not financial advice.